# An Open Label Positron Emission Tomography (PET) Study to Determine Central mGluR5 Receptor Occupancy of AZD2516

> **NCT00892944** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 6 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** AZD2516

## Key facts

- **NCT ID:** NCT00892944
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** —
- **Final completion:** 2009-10
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2009-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00892944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00892944, "An Open Label Positron Emission Tomography (PET) Study to Determine Central mGluR5 Receptor Occupancy of AZD2516". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00892944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*